PureTech Health plc (PTCHF)
USD 1.47
(-16.0%)
USD 1.47
(-16.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 125.58 Million USD | -19.01% |
| 2022 | 155.05 Million USD | -57.15% |
| 2021 | 361.85 Million USD | 7.55% |
| 2020 | 336.45 Million USD | 15.71% |
| 2019 | 290.78 Million USD | 5.82% |
| 2018 | 274.79 Million USD | -0.38% |
| 2017 | 275.84 Million USD | 33.69% |
| 2016 | 206.33 Million USD | 26.82% |
| 2015 | 162.7 Million USD | 72.46% |
| 2014 | 94.34 Million USD | 280.51% |
| 2013 | 24.79 Million USD | 10.0% |
| 2012 | 22.53 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 273.74 Million USD | 0.0% |
| 2024 Q1 | 273.74 Million USD | 117.98% |
| 2023 Q1 | 184.66 Million USD | 19.09% |
| 2023 Q3 | 235.74 Million USD | 27.66% |
| 2023 Q2 | 184.66 Million USD | 0.0% |
| 2023 FY | 125.58 Million USD | -19.01% |
| 2023 Q4 | 125.58 Million USD | -46.73% |
| 2022 Q1 | 247.12 Million USD | -31.71% |
| 2022 Q2 | 247.12 Million USD | 0.0% |
| 2022 FY | 155.05 Million USD | -57.15% |
| 2022 Q3 | 155.05 Million USD | -37.26% |
| 2022 Q4 | 155.05 Million USD | 0.0% |
| 2021 FY | 361.85 Million USD | 7.55% |
| 2021 Q2 | 335.51 Million USD | 0.0% |
| 2021 Q3 | 361.85 Million USD | 7.85% |
| 2021 Q1 | 335.51 Million USD | -0.28% |
| 2021 Q4 | 361.85 Million USD | 0.0% |
| 2020 Q1 | 338.64 Million USD | 16.46% |
| 2020 Q3 | 336.45 Million USD | -0.65% |
| 2020 Q4 | 336.45 Million USD | 0.0% |
| 2020 FY | 336.45 Million USD | 15.71% |
| 2020 Q2 | 338.64 Million USD | 0.0% |
| 2019 Q3 | 290.78 Million USD | -29.2% |
| 2019 FY | 290.78 Million USD | 5.82% |
| 2019 Q2 | 410.69 Million USD | 0.0% |
| 2019 Q1 | 410.69 Million USD | 49.46% |
| 2019 Q4 | 290.78 Million USD | 0.0% |
| 2018 Q1 | 215.95 Million USD | -21.71% |
| 2018 FY | 274.79 Million USD | -0.38% |
| 2018 Q4 | 274.79 Million USD | 3.4% |
| 2018 Q3 | 265.76 Million USD | 22.01% |
| 2018 Q2 | 217.81 Million USD | 0.86% |
| 2017 Q1 | 234.47 Million USD | 13.64% |
| 2017 FY | 275.84 Million USD | 33.69% |
| 2017 Q4 | 275.84 Million USD | 0.73% |
| 2017 Q3 | 273.86 Million USD | 15.65% |
| 2017 Q2 | 236.8 Million USD | 0.99% |
| 2016 Q1 | 185.75 Million USD | 14.17% |
| 2016 FY | 206.33 Million USD | 26.82% |
| 2016 Q4 | 206.33 Million USD | 1.11% |
| 2016 Q3 | 204.08 Million USD | 8.58% |
| 2016 Q2 | 187.96 Million USD | 1.19% |
| 2015 Q3 | 160.52 Million USD | 34.03% |
| 2015 FY | 162.7 Million USD | 72.46% |
| 2015 Q4 | 162.7 Million USD | 1.36% |
| 2015 Q2 | 119.76 Million USD | 0.79% |
| 2015 Q1 | 118.81 Million USD | 25.95% |
| 2014 Q4 | 94.34 Million USD | 0.71% |
| 2014 Q3 | 93.67 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 94.34 Million USD | 280.51% |
| 2013 FY | 24.79 Million USD | 10.0% |
| 2012 FY | 22.53 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | -73.287% |
| Neon Bloom, Inc. | 1.22 Million USD | -10141.532% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -15427.192% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -280871.452% |
| Qrons Inc. | 1.48 Million USD | -8335.676% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2295.708% |
| Skye Bioscience, Inc. | 14.07 Million USD | -792.417% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -112.802% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -457680.775% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -67.623% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -62343.068% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1226.685% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -135.593% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1210.611% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -29689.5% |
| SQZ Biotechnologies Company | 50.03 Million USD | -150.97% |
| Intellipharmaceutics International Inc. | 12 Million USD | -945.761% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3160.69% |
| Mesoblast Limited | 188.44 Million USD | 33.358% |
| Marizyme, Inc. | 26.67 Million USD | -370.777% |
| Genus plc | 485 Million USD | 74.107% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2049.429% |
| Pharming Group N.V. | 244.07 Million USD | 48.547% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -6147.506% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -4890.725% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3204.816% |
| ContraFect Corporation | 32.53 Million USD | -286.041% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -6238.389% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3180.944% |
| IMV Inc. | 37.93 Million USD | -231.067% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -966.233% |
| MultiCell Technologies, Inc. | 1617.67 USD | -7763102.631% |
| ONE Bio Corp. | 27.49 Million USD | -356.735% |
| Accustem Sciences Inc. | 1.07 Million USD | -11536.255% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -62.216% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -5837.537% |
| Q BioMed Inc. | 8.13 Million USD | -1444.128% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -51.423% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2340.384% |
| Biomind Labs Inc. | 1.49 Million USD | -8279.954% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -5.779% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1288.855% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -582.39% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -8658.38% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -88279.605% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -2085.641% |
| GB Sciences, Inc. | 5.41 Million USD | -2218.074% |
| Alpha Cognition Inc. | 7.16 Million USD | -1652.784% |
| HST Global, Inc. | 593.59 Thousand USD | -21056.415% |
| CSL Limited | 18.62 Billion USD | 99.326% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -9873.292% |
| Halberd Corporation | 728.71 Thousand USD | -17133.392% |
| Enzolytics Inc. | 365.26 Million USD | 65.619% |
| Agentix Corp. | 2.51 Million USD | -4902.201% |
| Resverlogix Corp. | 67.39 Million USD | -86.336% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -14872.959% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 71.776% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -7226.896% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -407.488% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -955.044% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3326.395% |
| AVAX Technologies, Inc. | 3.99 Million USD | -3044.492% |
| Zenith Capital Corp. | 27.56 Thousand USD | -455422.507% |
| Genscript Biotech Corporation | 1.32 Billion USD | 90.528% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -52521.368% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3262.954% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -18345.465% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -4531.255% |
| Kadimastem Ltd | 3.5 Million USD | -3483.103% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -187536.152% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -149.847% |
| BioStem Technologies, Inc. | 15.9 Million USD | -689.598% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -26924.59% |
| LadRx Corporation | 2.2 Million USD | -5606.949% |
| Cell Source, Inc. | 15.8 Million USD | -694.492% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2201.06% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2201.06% |
| NovAccess Global Inc. | 7.86 Million USD | -1497.599% |
| Affymax, Inc. | 8.87 Million USD | -1315.658% |
| Itoco Inc. | 1.65 Million USD | -7496.584% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -6021.327% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -1976.095% |
| Mobile Lads Corp. | 1.31 Million USD | -9460.966% |
| CytoDyn Inc. | 127.89 Million USD | 1.807% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -300344.987% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -7917.419% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1036.982% |
| SYBLEU INC | 681.41 Thousand USD | -18329.792% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1958.095% |
| International Stem Cell Corporation | 5.27 Million USD | -2279.818% |
| Bioxytran, Inc. | 3.24 Million USD | -3764.687% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -19967.305% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -2619.939% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -206.33% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -464.038% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -6100.445% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2192.497% |
| Neutra Corp. | 973.52 Thousand USD | -12799.77% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -332.821% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3242.529% |
| IXICO plc | 1.9 Million USD | -6508.616% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -511.735% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -21.543% |
| CSL Limited | 18.62 Billion USD | 99.326% |
| Cellectis S.A. | 249.36 Million USD | 49.64% |